Compare Okta, Inc. (OKTA) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Repligen Corporation Common Stock — how do they compare? Okta, Inc. trades at $206.8 (market cap $39.60B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Okta, Inc. is far larger — about 3.6× Repligen Corporation Common Stock's market cap, and Okta, Inc. is more actively traded (2,315,203 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Okta, Inc. for 44 Days and Repligen Corporation Common Stock for 0 Days on average.
| OKTA | RGEN | |
|---|---|---|
Market Cap | $39.60B | $11.14B |
Volume | 2,315,203 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $232.13 | $194.57 |
52-Week Low | $62.93 | $102.87 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $37.36B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $226.53, showing modest daily weakness with a 0.24% decline. The stock maintains strong bullish technical momentum with consistent earnings beats and positive analyst sentiment. Recent developments include the company's AI Agent Security Blueprint Alliance announcement at Oktane 2026, positioning Okta for growth in the emerging AI security market. Fundamental improvements show revenue growth from $2.3B in 2024 to $2.6B in 2025, with the company achieving profitability after several years of losses.
Outlook remains positive with 74% analyst buy ratings and a $245 high price target, though valuation multiples appear stretched with P/E of 136. Key risks include competitive pressures in cybersecurity and the stock's premium valuation. The transition to profitability and AI security positioning provide catalysts, but investors should monitor execution against growth expectations.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
